


Hikal Limited

Bonus of 1 equity share for every 2 shares

- ✓ Sales of Rs. 1,300 Crore; Growth of 26%
- ✓ EBITDA of Rs. 242 Crore; Growth of 23%
- ✓ Cash PAT of Rs. 163 Crore; Growth of 16%
- ✓ Total Dividend for the year - 60% (incl. interim dividend of 35%)

Mumbai, May 9th, 2018: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its audited financial results for the quarter and year ended 31st March, 2018.

Highlights for Year Ended 31st March, 2018



Performance highlights for the year ended 31st March, 2018

- **Sales up 26% to Rs. 1,300 crore** as compared to Rs. 1,034 crore in the corresponding period of the previous year
- **EBITDA up 23% to Rs. 242 crore** as compared to Rs. 197 crore in the corresponding period of the previous year
- **PAT higher by 9% to Rs. 77 crore** as compared to Rs. 71 crore in the corresponding period of the previous year
- **Cash PAT up 16% to Rs. 163 crore** as compared to Rs. 140 crore in the corresponding period of the previous year

Performance highlights for the quarter ended 31st March, 2018

- **Sales up 24% to Rs. 390 crore** as compared to Rs. 315 crore in the corresponding period of the previous year
- **EBITDA up 23% to Rs. 71 crore** as compared to Rs. 58 crore in the corresponding period of the previous year
- **PAT lower by 12% to Rs. 25 crore** as compared to Rs. 29 crore in the corresponding period of the previous year
- **Cash PAT up 2% to Rs. 47 crore** as compared to Rs. 46 crore in the corresponding period of the previous year

Segmental Performance for the year ended 31st March, 2018

- **Crop Protection sales up 29% to Rs. 547 crore** as compared to Rs. 423 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 23% to Rs. 753 crore** as compared to Rs. 611 crore in the corresponding period of the previous year

Segmental Performance for the quarter ended 31st March, 2018

- **Crop Protection sales up 28% to Rs. 176 crore** as compared to Rs. 137 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 21% to Rs. 215 crore** as compared to Rs. 178 crore in the corresponding period of the previous year

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“We had a strong performance this year with growth in revenues of 26%, EBITDA was up by 23% and a net profit of Rs. 77 crore. Our pharmaceutical division grew by 23% and our crop protection division by 29%.

Both the businesses showed growth from existing and new products. We are making significant capital investments in both our businesses for new products and capacity expansions in the coming year. Based on our results and future outlook, the board has recommended one bonus share for every two equity shares held, and maintained the total dividend of 60% as per the previous year. We are positive on the outlook for the coming financial year.”

About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal’s advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi
anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave
payal.dave@sgapl.net
+91 9819916314

www.sgapl.net
